Atenolol is a beta-blocker which is beta1-selective, (i.e. acts preferentially on beta1-adrenergic receptors in the heart). Atenolol is without intrinsic sympathomimetic and membrane-stabilising activities and as with other beta-blockers, has negative inotropic effects.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Atenolol is the active ingredient of these drugs:
Ecuador
Brazil
Hong Kong Singapore
Brazil
Ireland
Austria Cyprus Germany
Tunisia
Finland
Brazil
Brazil
South Africa
Ecuador
Brazil
Brazil
Austria
Ireland
Brazil
Tunisia
Hong Kong
Brazil
South Africa
Spain
Lithuania
Hong Kong
South Africa
Singapore
Tunisia
Tunisia
Hong Kong
Hong Kong
South Africa
Hong Kong Singapore
Hong Kong
Australia Hong Kong
Ecuador
Singapore
Italy
Hong Kong
Brazil Hong Kong
South Africa
Ecuador
Hong Kong
Singapore
New Zealand Singapore
Brazil
Australia
Italy
South Africa
Finland
Australia Austria Canada Cyprus Ecuador
France Tunisia
Hong Kong
Italy
Australia
Hong Kong
Hong Kong
Hong Kong
Cyprus Hong Kong
Cyprus Hong Kong Singapore Tunisia
Cyprus Singapore
Ecuador
South Africa
Atenolol is also found within below combination drugs:
ABLOK PLUS , ANGIPRESS CD , ATECOR CT , ATEHEXAL COMP , ATENETIC , ATENIDONE , ATENIGRON , ATENOCOMP , ATENOLAN-COMP , ATENORESE , BETA-DIPIN , BETA-NICARDIA , BETALOR , BLOKIUM-DIU , CLORTANOL , DIUBLOK , IGROSELES , KALTEN , NEATENOL DIU , NIF-TEN , NIFETEX , NIFTEN , PRETENOL C , REVERT , TARGET , TELOL C , TENCHLOR , TENDIURETIC , TENERETIC , TENIF , TENORDATE , TENORET , TENORETIC , TRI-NORMIN , TYPOFEN , VERICORDIN COMPUESTO